SMMT Q4 2023 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$840,000

Operating Income

-$28M

Net Income

-$29M

EPS (Diluted)

$-0.05

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$203M

Total Liabilities

$125M

Stockholders' Equity

$78M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$705	-100.0%
Gross Profit	-$840,000	-$595,000	-41.2%
Operating Income	-$28M	-$20M	-39.9%
Net Income	-$29M	-$19M	-49.2%